Jean-Pierre J Issa

List of Publications by Year in Descending Order

323 papers	39,831 citations	104 h-index	194 g-index
345 ext. papers	43,628 ext. citations	9.1 avg, IF	7.3 L-index

#	Paper	IF	Citations
323	The Two-Hit Hypothesis Meets Epigenetics.. *Cancer Research*, **2022**, 82, 1167-1169	10.1	1
322	Age-Related Variation in DNA Methylation **2022**, 235-259		
321	Accelerated aging in normal breast tissue of women with breast cancer. *Breast Cancer Research*, **2021**, 23, 58	8.3	3
320	High folic acid intake increases methylation-dependent expression of Lsr and dysregulates hepatic cholesterol homeostasis. *Journal of Nutritional Biochemistry*, **2021**, 88, 108554	6.3	0
319	Cellular Heterogeneity-Adjusted cLonal Methylation (CHALM) improves prediction of gene expression. *Nature Communications*, **2021**, 12, 400	17.4	5
318	Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. *Nature Communications*, **2021**, 12, 687	17.4	9
317	Promoter methylation changes in ALOX12 and AIRE1: novel epigenetic markers for atherosclerosis. *Clinical Epigenetics*, **2020**, 12, 66	7.7	5
316	Gestational high fat diet protects 3xTg offspring from memory impairments, synaptic dysfunction, and brain pathology. *Molecular Psychiatry*, **2019**,	15.1	3
315	Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. *Lancet Haematology,the* , **2019**, 6, e317-e327	14.6	54
314	Microbial Colonization Coordinates the Pathogenesis of a Klebsiella pneumoniae Infant Isolate. *Scientific Reports*, **2019**, 9, 3380	4.9	12
313	Aging-like Spontaneous Epigenetic Silencing Facilitates Wnt Activation, Stemness, and Braf-Induced Tumorigenesis. *Cancer Cell*, **2019**, 35, 315-328.e6	24.3	64
312	Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia. *Clinical Epigenetics*, **2019**, 11, 106	7.7	11
311	Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles. *Blood*, **2019**, 134, 2591-2591	2.2	8
310	Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients. *Blood*, **2019**, 134, 1319-1319	2.2	
309	Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. *Cell Reports*, **2019**, 26, 2241-2256.e4	10.6	15
308	DNA methylation aging clocks: challenges and recommendations. *Genome Biology*, **2019**, 20, 249	18.3	248
307	Demethylator phenotypes in acute myeloid leukemia. *Leukemia*, **2018**, 32, 2178-2188	10.7	5

306	Digital Restriction Enzyme Analysis of Methylation (DREAM). *Methods in Molecular Biology*, **2018**, 1708, 247-265	1.4	7
305	Roadmap for investigating epigenome deregulation and environmental origins of cancer. *International Journal of Cancer*, **2018**, 142, 874-882	7.5	46
304	Nerve Injury-Induced Chronic Pain Is Associated with Persistent DNA Methylation Reprogramming in Dorsal Root Ganglion. *Journal of Neuroscience*, **2018**, 38, 6090-6101	6.6	40
303	TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer. *Cancer Research*, **2018**, 78, 4126-4137	10.1	59
302	Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). *Blood*, **2018**, 132, 231-231	2.2	3
301	Engineering of CD19-Specific Chimeric Antigen Receptor T Cells with the Integrin CD103 Results in Augmented Therapeutic Efficacy Against Human Lymphoma in a Preclinical Model. *Blood*, **2018**, 132, 2050-2050	2.2	1
300	Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. *Cancer*, **2018**, 124, 325-334	6.4	43
299	Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer. *Cell*, **2018**, 175, 1244-1258.e26	56.2	102
298	Genetic Variants in Epigenetic Pathways and Risks of Multiple Cancers in the GAME-ON Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 816-825	4	7
297	DNA Hypomethylating Drugs in Cancer Therapy. *Cold Spring Harbor Perspectives in Medicine*, **2017**, 7,	5.4	69
296	The promise of epigenetic therapy: reprogramming the cancer epigenome. *Current Opinion in Genetics and Development*, **2017**, 42, 68-77	4.9	99
295	A novel isoform of TET1 that lacks a CXXC domain is overexpressed in cancer. *Nucleic Acids Research*, **2017**, 45, 8269-8281	20.1	25
294	Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome. *Molecular Cancer Therapeutics*, **2017**, 16, 397-407	6.1	42
293	Introduction: Cancer as an Epigenetic Disease. *Cancer Journal (Sudbury, Mass)*, **2017**, 23, 255-256	2.2	3
292	An Adverse Outcome Pathway Analysis Employing DNA Methylation Effects in Arsenic-Exposed Zebrafish Embryos Supports a Role of Epigenetic Events in Arsenic-Induced Chronic Disease. *Applied in Vitro Toxicology*, **2017**, 3, 312-324	1.3	2
291	Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. *Lancet Oncology, The*, **2017**, 18, 1317-1326	21.7	106
290	Caloric restriction delays age-related methylation drift. *Nature Communications*, **2017**, 8, 539	17.4	146
289	Epigenetics and Precision Oncology. *Cancer Journal (Sudbury, Mass)*, **2017**, 23, 262-269	2.2	40

288	Ezh2 phosphorylation state determines its capacity to maintain CD8 T memory precursors for antitumor immunity. *Nature Communications*, **2017**, 8, 2125	17.4	53
287	Transcriptional Selectivity of Epigenetic Therapy in Cancer. *Cancer Research*, **2017**, 77, 470-481	10.1	38
286	Targeting the cancer epigenome for therapy. *Nature Reviews Genetics*, **2016**, 17, 630-41	30.1	649
285	Zebrafish embryos as a screen for DNA methylation modifications after compound exposure. *Toxicology and Applied Pharmacology*, **2016**, 291, 84-96	4.6	42
284	Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas. *Epigenetics*, **2016**, 11, 184-93	5.7	36
283	Healthcare utilization and costs associated with tyrosine kinase inhibitor switching in patients with chronic myeloid leukemia. *Leukemia and Lymphoma*, **2016**, 57, 935-41	1.9	3
282	Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer. *Cancer Research*, **2016**, 76, 1494-505	10.1	68
281	Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. *Oncotarget*, **2016**, 7, 67495-67506	3.3	32
280	DNA Methyltransferase Inhibitors **2016**, 169-190		8
279	Diet, Nutrition, and Cancer Epigenetics. *Annual Review of Nutrition*, **2016**, 36, 665-81	9.9	94
278	Epigenetics and Cancer. *Energy Balance and Cancer*, **2016**, 1-28	0.2	2
277	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. *Mayo Clinic Proceedings*, **2015**, 90, 996-1000	6.4	105
276	Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. *Clinical Epigenetics*, **2015**, 7, 29	7.7	11
275	Epigenetic synergy between decitabine and platinum derivatives. *Clinical Epigenetics*, **2015**, 7, 97	7.7	25
274	New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development. *Cancer Prevention Research*, **2015**, 8, 1027-35	3.2	45
273	Minimal role of base excision repair in TET-induced global DNA demethylation in HEK293T cells. *Epigenetics*, **2015**, 10, 1006-13	5.7	18
272	Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. *Journal of Clinical Oncology*, **2015**, 33, 4032-8	2.2	424
271	Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. *Lancet Oncology, The*, **2015**, 16, 1099-1110	21.7	216

270	Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features. *Epigenetics*, **2015**, 10, 872-81	5.7	14
269	G9a is essential for epigenetic silencing of K(+) channel genes in acute-to-chronic pain transition. *Nature Neuroscience*, **2015**, 18, 1746-55	25.5	116
268	Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?. *Epigenomics*, **2015**, 7, 1083-8	4.4	8
267	Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia. *Journal of the National Cancer Institute*, **2015**, 108,	9.7	12
266	Epigenetics and Epigenetic Therapy of Cancer **2015**, 72-79		
265	TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia. *Cancer Research*, **2015**, 75, 2833-43	10.1	67
264	Regulation of AURKC expression by CpG island methylation in human cancer cells. *Tumor Biology*, **2015**, 36, 8147-58	2.9	7
263	Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. *Cancer*, **2015**, 121, 556-61	6.4	99
262	Hepatitis virus infection affects DNA methylation in mice with humanized livers. *Gastroenterology*, **2014**, 146, 562-72	13.3	80
261	Age-related epigenetic drift in the pathogenesis of MDS and AML. *Genome Research*, **2014**, 24, 580-91	9.7	62
260	Fusobacterium in colonic flora and molecular features of colorectal carcinoma. *Cancer Research*, **2014**, 74, 1311-8	10.1	289
259	A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. *British Journal of Haematology*, **2014**, 167, 185-93	4.5	100
258	Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples. *Clinical Epigenetics*, **2014**, 6, 13	7.7	7
257	BM-SNP: A Bayesian Model for SNP Calling Using High Throughput Sequencing Data. *IEEE/ACM Transactions on Computational Biology and Bioinformatics*, **2014**, 11, 1038-44	3	2
256	Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. *Science Translational Medicine*, **2014**, 6, 229ra41	17.5	63
255	TET1 is a maintenance DNA demethylase that prevents methylation spreading in differentiated cells. *Nucleic Acids Research*, **2014**, 42, 6956-71	20.1	90
254	Colorectal carcinomas with CpG island methylator phenotype 1 frequently contain mutations in chromatin regulators. *Gastroenterology*, **2014**, 146, 530-38.e5	13.3	61
253	Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors. *Clinical Epigenetics*, **2014**, 6, 2	7.7	8

252	Aging and epigenetic drift: a vicious cycle. *Journal of Clinical Investigation*, **2014**, 124, 24-9	15.9	257
251	Thalassemia due to intronic LINE-1 insertion in the globin gene (HBB): molecular mechanisms underlying reduced transcript levels of the globin(L1) allele. *Human Mutation*, **2013**, 34, 1361-5	4.7	10
250	Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma. *Cancer Research*, **2013**, 73, 4559-70	10.1	69
249	The myelodysplastic syndrome as a prototypical epigenetic disease. *Blood*, **2013**, 121, 3811-7	2.2	69
248	The epigenome of AML stem and progenitor cells. *Epigenetics*, **2013**, 8, 92-104	5.7	35
247	Epigenetic aspects of MDS and its molecular targeted therapy. *International Journal of Hematology*, **2013**, 97, 175-82	2.3	21
246	Examination of whole blood DNA methylation as a potential risk marker for gastric cancer. *Cancer Prevention Research*, **2013**, 6, 1093-100	3.2	31
245	Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties. *Scientific Reports*, **2013**, 3, 2687	4.9	94
244	Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. *Cancer Discovery*, **2013**, 3, 770-81	24.4	391
243	Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition. *Genome Biology*, **2013**, 14, R144	18.3	63
242	First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML). *Blood*, **2013**, 122, 497-497	2.2	20
241	Minoru Toyota: a tribute. *Tumor Biology*, **2012**, 33, 275-276	2.9	
240	Conserved DNA methylation patterns in healthy blood cells and extensive changes in leukemia measured by a new quantitative technique. *Epigenetics*, **2012**, 7, 1368-78	5.7	55
239	A Bayesian Model for SNP Discovery Based on Next-Generation Sequencing Data **2012**, 2012, 42-45		
238	SINE retrotransposons cause epigenetic reprogramming of adjacent gene promoters. *Molecular Cancer Research*, **2012**, 10, 1332-42	6.6	53
237	Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. *BMC Cancer*, **2012**, 12, 243	4.8	43
236	Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. *Cancer Cell*, **2012**, 21, 430-46	24.3	469
235	DNA methylation as a clinical marker in oncology. *Journal of Clinical Oncology*, **2012**, 30, 2566-8	2.2	45

234	Repetitive elements and enforced transcriptional repression co-operate to enhance DNA methylation spreading into a promoter CpG-island. *Nucleic Acids Research*, **2012**, 40, 7257-68	20.1	20
233	Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. *Epigenetics*, **2012**, 7, 201-7	5.7	103
232	Metabolic, hormonal and immunological associations with global DNA methylation among postmenopausal women. *Epigenetics*, **2012**, 7, 1020-8	5.7	34
231	A blueprint for an international cancer epigenome consortium. A report from the AACR Cancer Epigenome Task Force. *Cancer Research*, **2012**, 72, 6319-24	10.1	21
230	DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. *Cancer Research*, **2012**, 72, 1170-81	10.1	101
229	New DNA methylation markers associated with oral cancer (OC) development (dvlpt).. *Journal of Clinical Oncology*, **2012**, 30, 5524-5524	2.2	1
228	Age-Related Variation in DNA Methylation **2012**, 185-196		1
227	DNA methylation in normal colon^|^mdash;especially about ^|^quot;field cancerization^|^quot;. *Seibutsu Butsuri Kagaku*, **2012**, 56, 9-14		
226	Dnmt3a is essential for hematopoietic stem cell differentiation. *Nature Genetics*, **2011**, 44, 23-31	36.3	737
225	Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. *PLoS ONE*, **2011**, 6, e22110	3.7	83
224	Mechanisms of resistance to decitabine in the myelodysplastic syndrome. *PLoS ONE*, **2011**, 6, e23372	3.7	103
223	Histone deacetylase inhibitor activity in royal jelly might facilitate caste switching in bees. *EMBO Reports*, **2011**, 12, 238-43	6.5	132
222	Dissecting DNA hypermethylation in cancer. *FEBS Letters*, **2011**, 585, 2078-86	3.8	58
221	Epigenetics. *FEBS Letters*, **2011**, 585, 1993	3.8	8
220	DNA methylation predicts recurrence from resected stage III proximal colon cancer. *Cancer*, **2011**, 117, 1847-54	6.4	126
219	Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 1483-91	4	104
218	Time to think outside the (genetic) box. *Cancer Prevention Research*, **2011**, 4, 6-8	3.2	8
217	Chemoprevention of intestinal polyps in ApcMin/+ mice fed with western or balanced diets by drinking annurca apple polyphenol extract. *Cancer Prevention Research*, **2011**, 4, 907-15	3.2	44

216	DNA methylation profiles of primary colorectal carcinoma and matched liver metastasis. *PLoS ONE*, **2011**, 6, e27889	3.7	24
215	Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. *Clinical Cancer Research*, **2011**, 17, 4177-86	12.9	36
214	Frequent alteration of MLL3 frameshift mutations in microsatellite deficient colorectal cancer. *PLoS ONE*, **2011**, 6, e23320	3.7	53
213	Tumor-associated methylation of the putative tumor suppressor AJAP1 gene and association between decreased AJAP1 expression and shorter survival in patients with glioma. *Chinese Journal of Cancer*, **2011**, 30, 247-53		19
212	IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. *Carcinogenesis*, **2010**, 31, 342-9	4.6	81
211	Genome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancer. *Genome Research*, **2010**, 20, 1369-82	9.7	72
210	Association between folate levels and CpG Island hypermethylation in normal colorectal mucosa. *Cancer Prevention Research*, **2010**, 3, 1552-64	3.2	102
209	Widespread and tissue specific age-related DNA methylation changes in mice. *Genome Research*, **2010**, 20, 332-40	9.7	391
208	DNA methylation profiling in cancer. *Expert Reviews in Molecular Medicine*, **2010**, 12, e23	6.7	28
207	Decitabine in the treatment of myelodysplastic syndromes. *Expert Review of Anticancer Therapy*, **2010**, 10, 9-22	3.5	50
206	DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. *Journal of Clinical Oncology*, **2010**, 28, 605-13	2.2	285
205	Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation. *Cancer Research*, **2010**, 70, 6968-77	10.1	63
204	Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. *Leukemia and Lymphoma*, **2010**, 51, 73-8	1.9	32
203	Current and future management options for myelodysplastic syndromes. *Drugs*, **2010**, 70, 1381-94	12.1	9
202	Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. *Clinical Lymphoma, Myeloma and Leukemia*, **2010**, 10, 205-10	2	17
201	Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. *Clinical Cancer Research*, **2010**, 16, 3539-47	12.9	97
200	Epigenetic changes in the myelodysplastic syndrome. *Hematology/Oncology Clinics of North America* , **2010**, 24, 317-30	3.1	80
199	Epigenetic mechanisms in AML - a target for therapy. *Cancer Treatment and Research*, **2010**, 145, 19-40	3.5	44

198	Cancer epigenetics. *Ca-A Cancer Journal for Clinicians*, **2010**, 60, 376-92	220.7	330
197	Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. *Cancer*, **2010**, 116, 3830-4	6.4	195
196	Characteristic methylation profile in CpG island methylator phenotype-negative distal colorectal cancers. *International Journal of Cancer*, **2010**, 127, 2095-105	7.5	31
195	Aging and DNA Methylation. *Current Chemical Biology*, **2009**, 3, 1-9	0.4	4
194	Analysis of epigenetic modifications by next generation sequencing. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*, **2009**, 2009, 6730	0.9	2
193	LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. *Epigenetics*, **2009**, 4, 176-84	5.7	50
192	Global DNA hypomethylation (LINE-1) in the normal colon and lifestyle characteristics and dietary and genetic factors. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 1041-9	4	123
191	Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. *Clinical Cancer Research*, **2009**, 15, 3881-8	12.9	102
190	Concordant DNA methylation in synchronous colorectal carcinomas. *Cancer Prevention Research*, **2009**, 2, 814-22	3.2	34
189	The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?. *Cancer*, **2009**, 115, 5202-9	6.4	36
188	Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. *Cancer*, **2009**, 115, 5746-51	6.4	83
187	Using short-term response information to facilitate adaptive randomization for survival clinical trials. *Statistics in Medicine*, **2009**, 28, 1680-9	2.3	41
186	Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. *Leukemia*, **2009**, 23, 1605-13	10.7	77
185	Hypomethylation of long interspersed nuclear element-1 in hepatocellular carcinomas. *Modern Pathology*, **2009**, 22, 442-9	9.8	39
184	Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. *Bone Marrow Transplantation*, **2009**, 43, 839-43	4.4	63
183	Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. *Cancer Research*, **2009**, 69, 9073-82	10.1	105
182	Histone deacetylase inhibitors as anti-neoplastic agents. *Cancer Letters*, **2009**, 280, 192-200	9.9	133
181	Histone deacetylase inhibition elicits an evolutionarily conserved self-renewal program in embryonic stem cells. *Cell Stem Cell*, **2009**, 4, 359-69	18	136

180	Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines. *Blood*, **2009**, 113, 659-67	2.2	190
179	Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes. *Gastroenterology*, **2009**, 136, 2149-58	13.3	101
178	Targeting DNA methylation. *Clinical Cancer Research*, **2009**, 15, 3938-46	12.9	328
177	Tackling the methylome: recent methodological advances in genome-wide methylation profiling. *Genome Medicine*, **2009**, 1, 106	14.4	21
176	CpG island methylation profiling in human melanoma cell lines. *Melanoma Research*, **2009**, 19, 146-55	3.3	79
175	Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. *Blood*, **2009**, 114, 1859-63	2.2	212
174	Aging and DNA Methylation. *Current Chemical Biology*, **2009**, 3, 321-329	0.4	5
173	Digital Restriction Enzyme Analysis of Methylation (DREAM) by Next Generation Sequencing Yields High Resolution Maps of DNA Methylation.. *Blood*, **2009**, 114, 567-567	2.2	1
172	Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. *Laboratory Investigation*, **2008**, 88, 694-721	5.9	55
171	Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. *Leukemia*, **2008**, 22, 1529-38	10.7	132
170	Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. *Nature Genetics*, **2008**, 40, 741-50	36.3	520
169	Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. *PLoS ONE*, **2008**, 3, e2037	3.7	195
168	Methylated CpG Island Amplification and Microarray (MCAM) for High-Throughput Analysis of DNA Methylation. *Cold Spring Harbor Protocols*, **2008**, 2008, pdb.prot4974	1.2	5
167	Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. *Leukemia and Lymphoma*, **2008**, 49, 690-5	1.9	92
166	Cancer prevention: epigenetics steps up to the plate. *Cancer Prevention Research*, **2008**, 1, 219-22	3.2	42
165	Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. *Carcinogenesis*, **2008**, 29, 1901-10	4.6	106
164	An Sp1/Sp3 binding polymorphism confers methylation protection. *PLoS Genetics*, **2008**, 4, e1000162	6	58
163	Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. *Clinical Cancer Research*, **2008**, 14, 2560-9	12.9	86

162	Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance. *Clinical Cancer Research*, **2008**, 14, 2664-72	12.9	33
161	15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation. *FASEB Journal*, **2008**, 22, 1981-92	0.9	19
160	Colon cancer: it's CIN or CIMP. *Clinical Cancer Research*, **2008**, 14, 5939-40	12.9	106
159	Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. *Blood*, **2008**, 111, 2382-4	2.2	63
158	Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. *Blood*, **2008**, 112, 1366-73	2.2	124
157	Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. *Cancer*, **2008**, 112, 1489-502	6.4	130
156	Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. *Cancer*, **2008**, 112, 2341-51	6.4	143
155	Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. *Cancer*, **2008**, 113, 1933-52	6.4	74
154	Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. *Cancer*, **2008**, 113, 1351-61	6.4	386
153	Randomized Phase II Study of Combined Epigenetic Therapy: Decitabine Vs. Decitabine and Valproic Acid in MDS and AML. *Blood*, **2008**, 112, 228-228	2.2	13
152	Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. *PLoS ONE*, **2008**, 3, e2079	3.7	97
151	Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. *Blood*, **2007**, 110, 2302-8	2.2	347
150	High-throughput methylation profiling by MCA coupled to CpG island microarray. *Genome Research*, **2007**, 17, 1529-36	9.7	137
149	Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias. *Gastroenterology*, **2007**, 132, 1254-60	13.3	77
148	LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. *PLoS ONE*, **2007**, 2, e399	3.7	202
147	Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. *Cancer*, **2007**, 109, 265-73	6.4	94
146	Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. *Cancer*, **2007**, 109, 899-906	6.4	115
145	Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. *Cancer*, **2007**, 109, 1133-7	6.4	158

144	Decitabine--bedside to bench. *Critical Reviews in Oncology/Hematology*, **2007**, 61, 140-52	7	134
143	Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. *Nature Medicine*, **2007**, 13, 78-83	50.5	164
142	Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors). *Modern Pathology*, **2007**, 20, 802-10	9.8	119
141	Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome. *British Journal of Haematology*, **2007**, 138, 555-7	4.5	5
140	Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition. *British Journal of Haematology*, **2007**, 138, 616-23	4.5	31
139	A parallel phase I/II clinical trial design for combination therapies. *Biometrics*, **2007**, 63, 429-36	1.8	82
138	Epigenetic control of PRV-1 expression on neutrophils. *Experimental Hematology*, **2007**, 35, 1677-83	3.1	10
137	Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. *Cancer Research*, **2007**, 67, 11335-43	10.1	96
136	Treatment options in advanced myelodysplastic syndrome, with emphasis on epigenetic therapy. *International Journal of Hematology*, **2007**, 86, 306-14	2.3	14
135	Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 18654-9	11.5	446
134	Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. *Journal of Clinical Oncology*, **2007**, 25, 2164-70	2.2	314
133	DNA methylation as a therapeutic target in cancer. *Clinical Cancer Research*, **2007**, 13, 1634-7	12.9	237
132	Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. *Clinical Cancer Research*, **2007**, 13, 6093-8	12.9	153
131	Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 13732-7	11.5	40
130	Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. *PLoS Genetics*, **2007**, 3, 2023-36	6	277
129	Effect of cytarabine and decitabine in combination in human leukemic cell lines. *Clinical Cancer Research*, **2007**, 13, 4225-32	12.9	97
128	PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL. *Cancer Biology and Therapy*, **2007**, 6, 1967-77	4.6	27
127	Age-related DNA methylation changes in normal human prostate tissues. *Clinical Cancer Research*, **2007**, 13, 3796-802	12.9	182

126	RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. *Cancer Research*, **2007**, 67, 1997-2005	10.1	61
125	Delta DNMT3B variants regulate DNA methylation in a promoter-specific manner. *Cancer Research*, **2007**, 67, 10647-52	10.1	45
124	Optimizing annealing temperature overcomes bias in bisulfite PCR methylation analysis. *BioTechniques*, **2007**, 42, 48, 50, 52 passim	2.5	106
123	Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. *Blood*, **2007**, 109, 52-7	2.2	577
122	Response: Decitabine response with chromosome 7 abnormality in MDS, and decitabine optimal schedule. *Blood*, **2007**, 110, 1083-1083	2.2	2
121	RPS19 and JAK2 genes are not silenced by DNA methylation in diamond blackfan anemia. *Journal of Pediatric Hematology/Oncology*, **2007**, 29, 207-8	1.2	1
120	Targeting aberrant chromatin structure in colorectal carcinomas. *Cancer Journal (Sudbury, Mass)*, **2007**, 13, 49-55	2.2	16
119	Epigenetic changes in estrogen receptor beta gene in atherosclerotic cardiovascular tissues and in-vitro vascular senescence. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2007**, 1772, 72-80	6.9	128
118	Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. *Hepatology Research*, **2007**, 37, 974-83	5.1	168
117	Correlation between CpG methylation profiles and hormone receptor status in breast cancers. *Breast Cancer Research*, **2007**, 9, R57	8.3	112
116	Decitabine and its role in the treatment of hematopoietic malignancies. *Leukemia and Lymphoma*, **2007**, 48, 1472-81	1.9	88
115	Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) and Decitabine in Patients with Relapsed, Refractory or Poor Prognosis Leukemia.. *Blood*, **2007**, 110, 897-897	2.2	10
114	PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter. *Annals of Hematology*, **2006**, 85, 689-704	3	17
113	Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. *Cancer*, **2006**, 106, 1794-803	6.4	1228
112	Phase I trial of sequential low-dose 5-aza-2′-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. *Clinical Cancer Research*, **2006**, 12, 4619-27	12.9	120
111	Silencing of bidirectional promoters by DNA methylation in tumorigenesis. *Cancer Research*, **2006**, 66, 5077-84	10.1	81
110	Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast cancers. *Methods in Enzymology*, **2006**, 407, 455-68	1.7	48
109	Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer. *Cancer Biology and Therapy*, **2006**, 5, 1494-501	4.6	53

108	Phase 1/2 study of the combination of 5-aza-2Θdeoxycytidine with valproic acid in patients with leukemia. *Blood*, **2006**, 108, 3271-9	2.2	441
107	DNA methylation changes after 5-aza-2Θdeoxycytidine therapy in patients with leukemia. *Cancer Research*, **2006**, 66, 5495-503	10.1	231
106	Review: recent clinical trials in epigenetic therapy. *Reviews on Recent Clinical Trials*, **2006**, 1, 169-82	1.2	47
105	Phase I/II Study of the Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor MGCD0103 in Combination with Azacitidine in Patients (pts) with High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML).. *Blood*, **2006**, 108, 1954-1954	2.2	7
104	Hypomethylation Induction and Molecular Response after Decitabine Therapy in Chronic Myelomonocytic Leukemia (CMML).. *Blood*, **2006**, 108, 2322-2322	2.2	1
103	Decitabine Induces Responses in Patients with Myelodysplastic Syndrome (MDS) after Failure of Azacitidine Therapy.. *Blood*, **2006**, 108, 518-518	2.2	2
102	Mutations and promoter methylation status of NPM1 in myeloproliferative disorders. *Haematologica*, **2006**, 91, 1147-8	6.6	22
101	Decitabine in chronic leukemias. *Seminars in Hematology*, **2005**, 42, S43-9	4	13
100	Decitabine dosing schedules. *Seminars in Hematology*, **2005**, 42, S17-22	4	34
99	Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents. *Cancer Investigation*, **2005**, 23, 635-42	2.1	81
98	BRAF mutations in aberrant crypt foci and hyperplastic polyposis. *American Journal of Pathology*, **2005**, 166, 1069-75	5.8	104
97	The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. *Gastroenterology*, **2005**, 129, 156-69	13.3	116
96	Phenotype of microsatellite-stable colorectal carcinomas with CpG island methylation. *American Journal of Surgical Pathology*, **2005**, 29, 429-36	6.7	54
95	Decitabine in myelodysplastic syndromes. *Therapy: Open Access in Clinical Medicine*, **2005**, 2, 835-842		3
94	Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia. *Leukemia Research*, **2005**, 29, 881-5	2.7	15
93	Aberrant DNA methylation associated with silencing BNIP3 gene expression in haematopoietic tumours. *British Journal of Cancer*, **2005**, 92, 1165-72	8.7	75
92	Azacitidine. *Nature Reviews Drug Discovery*, **2005**, 4, 275-6	64.1	109
91	Epigenetic changes in solid and hematopoietic tumors. *Seminars in Oncology*, **2005**, 32, 521-30	5.5	103

90	Living Longer: The Aging Epigenome **2005**, 139-149		
89	Azacitidine. *Nature Reviews Drug Discovery*, **2005**, Suppl, S6-7	64.1	43
88	Differing DNA methylation patterns and gene mutation frequencies in colorectal carcinomas from Middle Eastern countries. *Clinical Cancer Research*, **2005**, 11, 8281-7	12.9	35
87	MGMT promoter methylation and field defect in sporadic colorectal cancer. *Journal of the National Cancer Institute*, **2005**, 97, 1330-8	9.7	399
86	Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. *Journal of Clinical Oncology*, **2005**, 23, 3948-56	2.2	259
85	Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection. *Nature Clinical Practice Oncology*, **2005**, 2 Suppl 1, S24-9		68
84	JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. *Blood*, **2005**, 106, 3370-3	2.2	312
83	Phase II Study of Decitabine in Combination with Imatinib Mesylate in Patients with Accelerated (AP) or Blastic Phase (BP) of Chronic Myeloid Leukemia (CML).. *Blood*, **2005**, 106, 1099-1099	2.2	3
82	Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome.. *Blood*, **2005**, 106, 2801-2801	2.2	13
81	Final Results of a Phase I/II Study of the Combination of the Hypomethylating Agent 5-aza-2?-Deoxycytidine (DAC) and the Histone Deacetylase Inhibitor Valproic Acid (VPA) in Patients with Leukemia.. *Blood*, **2005**, 106, 408-408	2.2	2
80	CpG Island Methylation Is a Poor Prognostic Factors in Myelodysplastic Syndrome Patients and Is Reversed by Decitabine Therapy-Results of a Phase III Randomized Study.. *Blood*, **2005**, 106, 790-790	2.2	4
79	Decitabine in myelodysplastic syndromes. *Therapy: Open Access in Clinical Medicine*, **2005**, 2, 835-842		
78	Myelodysplastic syndromes. *Hematology American Society of Hematology Education Program*, **2004**, 2004, 297-317	3.1	93
77	Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. *Clinical Cancer Research*, **2004**, 10, 1733-42	12.9	111
76	Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers. *Cancer Research*, **2004**, 64, 2411-7	10.1	77
75	Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: incidence and potential implications. *Clinical Cancer Research*, **2004**, 10, 3825-30	12.9	119
74	Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 7398-403	11.5	136
73	Regulation of RARbeta1 expression in head and neck cancer cells by cell density-dependent chromatin remodeling. *Cancer Biology and Therapy*, **2004**, 3, 1002-6	4.6	6

72	Methylation and regulation of expression of different retinoic acid receptor beta isoforms in human colon cancer. *Cancer Biology and Therapy*, **2004**, 3, 82-6	4.6	31
71	CpG island methylator phenotype in cancer. *Nature Reviews Cancer*, **2004**, 4, 988-93	31.3	870
70	Epigenetic changes in colorectal cancer. *Cancer and Metastasis Reviews*, **2004**, 23, 29-39	9.6	243
69	Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2Θdeoxycytidine (decitabine) in hematopoietic malignancies. *Blood*, **2004**, 103, 1635-40	2.2	694
68	A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. *Nucleic Acids Research*, **2004**, 32, e38	20.1	791
67	Identification of 41 Novel Promoter-Associated CpG Islands Methylated in Leukemias.. *Blood*, **2004**, 104, 1126-1126	2.2	3
66	First Report of the Phase III North American Trial of Decitabine in Advanced Myelodysplastic Syndrome (MDS).. *Blood*, **2004**, 104, 67-67	2.2	28
65	Epigenetic inactivation of CHFR in human tumors. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 7818-23	11.5	171
64	Mitoxantrone: a hypomethylating agent?. *Cancer Biology and Therapy*, **2003**, 2, 264-5	4.6	2
63	Comment on "Chromosomal instability and tumors promoted by DNA hypomethylation" and "Induction of tumors in nice by genomic hypomethylation". *Science*, **2003**, 302, 1153; author reply 1153	33.3	18
62	Decitabine. *Current Opinion in Oncology*, **2003**, 15, 446-51	4.2	67
61	Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. *Blood*, **2003**, 101, 4131-6	2.2	113
60	Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia. *Cancer*, **2003**, 97, 695-702	6.4	59
59	Results of decitabine (5-aza-2Θdeoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. *Cancer*, **2003**, 98, 522-8	6.4	200
58	CpG island methylation in carcinoid and pancreatic endocrine tumors. *Oncogene*, **2003**, 22, 924-34	9.2	114
57	Comparison of epigenetic and genetic alterations in mucinous cystic neoplasm and serous microcystic adenoma of pancreas. *Modern Pathology*, **2003**, 16, 1086-94	9.8	75
56	Epigenetic regulation of ARHI in breast and ovarian cancer cells. *Annals of the New York Academy of Sciences*, **2003**, 983, 268-77	6.5	69
55	Epigenetic and genetic alterations in duodenal carcinomas are distinct from biliary and ampullary carcinomas. *Gastroenterology*, **2003**, 124, 1300-10	13.3	37

54	P14 methylation in human colon cancer is associated with microsatellite instability and wild-type p53. *Gastroenterology*, **2003**, 124, 626-33	13.3	79
53	Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. *Molecular and Cellular Biology*, **2003**, 23, 206-15	4.8	302
52	Age-related epigenetic changes and the immune system. *Clinical Immunology*, **2003**, 109, 103-8	9	155
51	SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 8412-7	11.5	243
50	Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. *Human Molecular Genetics*, **2003**, 12, 1791-800	5.6	62
49	Enrichment for histone H3 lysine 9 methylation at Alu repeats in human cells. *Journal of Biological Chemistry*, **2003**, 278, 27658-62	5.4	96
48	Comment on "Chromosomal Instability and Tumors Promoted by DNA Hypomethylation" and "Induction of Tumors in Mice by Genomic Hypomethylation". *Science*, **2003**, 302, 1153b-1153	33.3	55
47	Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. *Cancer Research*, **2003**, 63, 4174-80	10.1	63
46	Methylation and prognosis: of molecular clocks and hypermethylator phenotypes. *Clinical Cancer Research*, **2003**, 9, 2879-81	12.9	45
45	Association of the CpG island methylator phenotype with family history of cancer in patients with colorectal cancer. *Cancer Research*, **2003**, 63, 4805-8	10.1	65
44	Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. *Cancer Research*, **2003**, 63, 7089-93	10.1	185
43	Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer. *Clinical Cancer Research*, **2003**, 9, 6410-8	12.9	42
42	Epigenetic variation and human disease. *Journal of Nutrition*, **2002**, 132, 2388S-2392S	4.1	93
41	Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors. *Oncogene*, **2002**, 21, 2741-9	9.2	108
40	HLTF gene silencing in human colon cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 4562-7	11.5	127
39	DNA methylation and environmental exposures in human hepatocellular carcinoma. *Journal of the National Cancer Institute*, **2002**, 94, 755-61	9.7	204
38	Methylated CpG island amplification for methylation analysis and cloning differentially methylated sequences. *Methods in Molecular Biology*, **2002**, 200, 101-10	1.4	6
37	Epigenetics in colorectal cancer. *Current Opinion in Gastroenterology*, **2002**, 18, 68-73	3	25

36	Lack of p21(CIP1) DNA methylation in acute lymphocytic leukemia. *Blood*, **2002**, 100, 3432-3; author reply 3433-4	2.2	21
35	CpG island methylation in aberrant crypt foci of the colorectum. *American Journal of Pathology*, **2002**, 160, 1823-30	5.8	187
34	Concordant CpG island methylation in hyperplastic polyposis. *American Journal of Pathology*, **2002**, 160, 529-36	5.8	160
33	Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. *Clinical Cancer Research*, **2002**, 8, 1178-84	12.9	278
32	DNA methylation patterns at relapse in adult acute lymphocytic leukemia. *Clinical Cancer Research*, **2002**, 8, 1897-903	12.9	55
31	Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. *Clinical Cancer Research*, **2002**, 8, 2167-76	12.9	72
30	Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. *Clinical Cancer Research*, **2002**, 8, 2177-87	12.9	84
29	DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. *Clinical Cancer Research*, **2002**, 8, 2217-24	12.9	137
28	Methylation profiling in acute myeloid leukemia. *Blood*, **2001**, 97, 2823-9	2.2	274
27	Genomic structure and promoter characterization of an imprinted tumor suppressor gene ARHI. *Biochimica Et Biophysica Acta Gene Regulatory Mechanisms*, **2001**, 1519, 216-22		31
26	Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. *Annals of Internal Medicine*, **2001**, 134, 573-86	8	309
25	CpG island methylation in colorectal adenomas. *American Journal of Pathology*, **2001**, 159, 1129-35	5.8	181
24	The epigenetics of colorectal cancer. *Annals of the New York Academy of Sciences*, **2000**, 910, 140-53; discussion 153-5	6.5	81
23	The role of DNA hypermethylation in human neoplasia. *Electrophoresis*, **2000**, 21, 329-33	3.6	48
22	Methylation of the estrogen receptor-alpha gene promoter is selectively increased in proliferating human aortic smooth muscle cells. *Cardiovascular Research*, **2000**, 46, 172-9	9.9	94
21	Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 710-5	11.5	378
20	Methylation of the ABL1 Promoter in Chronic Myelogenous Leukemia: Lack of Prognostic Significance. *Blood*, **1999**, 93, 2075-2080	2.2	65
19	CpG island methylator phenotype in colorectal cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 8681-6	11.5	1985

18	Aging, DNA methylation and cancer. *Critical Reviews in Oncology/Hematology*, **1999**, 32, 31-43	7	154
17	Methylation and silencing of the Thrombospondin-1 promoter in human cancer. *Oncogene*, **1999**, 18, 3284-9	9.2	142
16	CpG island methylator phenotypes in aging and cancer. *Seminars in Cancer Biology*, **1999**, 9, 349-57	12.7	219
15	Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. *Cardiovascular Research*, **1999**, 43, 985-91	9.9	363
14	Concordant methylation of the ER and N33 genes in glioblastoma multiforme. *Oncogene*, **1998**, 16, 3197-202	9.2	65
13	Infection with human immunodeficiency virus type 1 upregulates DNA methyltransferase, resulting in de novo methylation of the gamma interferon (IFN-gamma) promoter and subsequent downregulation of IFN-gamma production. *Molecular and Cellular Biology*, **1998**, 18, 5166-77	4.8	139
12	Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 6870-5	11.5	1541
11	Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia. *Advances in Cancer Research*, **1997**, 141-196	5.9	1277
10	Increased cytosine DNA-methyltransferase activity is target-cell-specific and an early event in lung cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **1996**, 93, 4045-50	11.5	217
9	Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **1996**, 93, 11757-62	11.5	219
8	Epigenetics and human disease. *Nature Medicine*, **1996**, 2, 281-2	50.5	31
7	p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. *Nature Medicine*, **1995**, 1, 570-7	50.5	376
6	A microassay for measuring cytosine DNA methyltransferase activity during tumor progression. *Toxicology Letters*, **1995**, 82-83, 335-40	4.4	7
5	Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. *Nature Genetics*, **1994**, 7, 536-40	36.3	1005
4	Expression of an exogenous eukaryotic DNA methyltransferase gene induces transformation of NIH 3T3 cells. *Proceedings of the National Academy of Sciences of the United States of America*, **1993**, 90, 8891-5	11.5	225
3	DNA-methylation inhibitors908-911		
2	Comparative Modeling of CDK9 Inhibitors to Explore Selectivity and Structure-Activity Relationships		2
1	TET1andTDGsuppress intestinal tumorigenesis by down-regulating the inflammatory and immune response pathways		1